Kinnate Biopharma Inc. Closes $35 Million Series A
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture May 13, 2021 16:02 ET | Source: Kinnate Biopharma Kinnate Biopharma Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital The joint venture will have exclusive license to develop and commercialize Kinnate’s currently most advanced kinase inhibitor candidates in Greater China Veteran biopharmaceutical industry executive Wenn Sun, Ph.D. has been named as Executive Chair SAN FRANCISCO and SAN DIEGO, May 13, 2021 ...
Source: globenewswire.com